Targeted radiation and chemo before donor stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer like acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), a pre-leukemia condition (MDS), or myelofibrosis (MF).
- You are either 70 or older, OR between 18 and 69 and have high-risk disease (for example, your cancer has certain chromosome changes or it came back after treatment).
- Your cancer cells show a marker called CD38 (this is checked with a lab test).
- You have a brother, sister, or unrelated donor who matches your tissue type for stem cell donation.
- You are active enough to take care of most daily tasks (Karnofsky score 70% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a radioactive drug, 131I-apamistamab, given before a donor stem cell transplant to help the transplant work better in people with relapsed or hard-to-treat acute myeloid leukemia (AML). The drug targets a protein on leukemia cells to deliver radiation directly to the cancer, potentially improving outcomes with fewer side effects than standard high-dose chemo.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.